This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| A. | Classification code — C33 (malignant neoplasm of trachea) |
| B. | Synonyms — tracheal cancer, tracheal adenoid cystic carcinoma, tracheal squamous cell carcinoma, tracheal carcinoma |
| C. | Adult onset — very high (mainly 40s–70s; adenoid cystic carcinoma in the 40s–50s; squamous cell carcinoma in the 60s–70s) |
| 1. | History — rarity of tracheal cancer and delayed recognition; development of tracheal resection and reconstruction; Grillo's pioneering tracheal surgery |
| 2. | Causes — smoking (squamous cell carcinoma), asbestos and radiation exposure, chronic respiratory infection, rarely genetic predisposition |
| 3. | Genetics — SCC: TP53, CDKN2A; ACC (adenoid cystic): MYB-NFIB fusion, NOTCH1; NTRK fusion |
| 4. | Epidemiology — less than 0.1% of all malignancies; about 2,000 cases per year worldwide; male predominance; rare cancer |
| 5. | Pathophysiology — squamous metaplasia of the tracheal mucosa (SCC); intestinal-type exocrine glands of the tracheal submucosa (ACC); secondary invasion of the trachea (rare) |
| 6. | Symptoms — dyspnea·wheezing (appear after progression), cough, blood-tinged sputum, dysphagia; nonspecific symptoms → delayed diagnosis |
| 7. | Signs — inspiratory and expiratory wheezing, hoarseness (vocal cord nerve invasion), superior vena cava syndrome, airway stenosis |
| 8. | Screening — no standard screening; tracheoscopy performed when following tracheal foreign bodies or chronic stenosis |
| 9. | Diagnosis — bronchoscopic (tracheoscopic) biopsy, chest CT·MRI, PET-CT, flow-volume curve, histologic classification |
| 10. | Treatment — tracheal resection and reconstruction (curative); radiotherapy (inoperable); palliative tracheal stent; chemotherapy |
| 11. | Prognosis — ACC 5-year survival about 52%; SCC about 39%; markedly poor with incomplete resection (R1/R2) |
| 12. | Prevention — smoking cessation, prevention of occupational asbestos and radiation exposure, management of chronic respiratory disease, early removal of tracheal foreign bodies |
| 13. | References — 10 items on tracheal cancer epidemiology, surgery and radiotherapy |
Special Copayment Reduction (V193): 5% copayment applied for 5 years from the cancer patient registration date
| Category | Details |
|---|---|
| ICD-10 code | C33 — malignant neoplasm of trachea (single code) |
| Korean Standard Classification of Diseases code | C33 (applied identically under KCD-8) |
| Special Copayment Reduction code | V193 |
| Main histological types | Squamous cell carcinoma (SCC) about 50–60%, adenoid cystic carcinoma (ACC) about 15–20%, others (adenocarcinoma, carcinoid, small cell carcinoma, mucoepidermoid carcinoma, chondrosarcoma, etc.) |
| Differential | Secondary invasion from adjacent organs (lung, esophagus, thyroid, larynx) must be differentiated from primary tracheal cancer; note that primary tracheal cancer is rarer than secondary tracheal invasion by lung cancer |
Tracheal cancer, malignant neoplasm of trachea, tracheal adenoid cystic carcinoma, tracheal squamous cell carcinoma, tracheal carcinoma, primary tracheal malignancy, primary tracheal tumor (which rarely includes benign tumors, but limited to malignant here). Tracheal cancer is an extremely rare cancer accounting for less than 0.1% of all malignancies and belongs to the rare cancer category.
Tracheal cancer is a disease with a very high frequency of adult onset, and the age of onset differs by histologic type. Squamous cell carcinoma is closely related to smoking and occurs mainly in men in their 60s–70s. Adenoid cystic carcinoma (ACC) is less associated with smoking, also occurs in relatively younger people in their 40s–50s, and shows little sex difference. It is extremely rare in children.
Primary malignant tumors of the trachea are extremely rare, so large single-institution studies have historically been difficult. Pathologic case reports began in the late 19th century, and because cases were often mistaken for tracheal invasion by lung or laryngeal cancer rather than tracheal cancer itself, accurate diagnosis and classification were delayed. In the early 20th century, advances in tracheoscopy (bronchoscopy; Killian's rigid tracheoscope introduced in 1897) made direct observation and biopsy of intratracheal lesions possible.
In surgical treatment, the pioneer of tracheal resection and reconstruction was Hermes Grillo (Massachusetts General Hospital), who in the 1960s–1970s established the limits for safely performing circumferential tracheal resection and primary anastomosis (about 4–6 rings resected, 6 cm or less). Grillo's work opened the possibility of surgical treatment for tracheal tumors previously regarded as incurable. The primary tracheal origin of adenoid cystic carcinoma (ACC) was established in a series of case studies in the 1950s–1960s, and the distinctive biologic features of ACC—slow growth and relatively long survival even after distant metastasis—became known.
Regarding radiotherapy, several retrospective studies have confirmed that radiotherapy alone in inoperable patients, or combined postoperative radiotherapy, helps local control of tracheal cancer. Recently, proton therapy and interventional bronchoscopy (interventional tracheoscopy, laser ablation, electrocautery, tracheal stent insertion) have been used as palliative treatments for symptom relief and airway patency. Because of its rarity, no randomized controlled trials exist, and all evidence for tracheal cancer treatment is based on retrospective single-institution studies or case reports.
Smoking is the most important risk factor for tracheal squamous cell carcinoma, with markedly increased risk in smokers compared with nonsmokers. Carcinogens in tobacco smoke (PAH, nitrosamines, etc.) directly contact the tracheal mucosa and cause DNA damage. Adenoid cystic carcinoma (ACC) is less associated with smoking than squamous cell carcinoma. Asbestos exposure is reported as a risk factor for tracheal cancer (IARC Group 1). Ionizing radiation exposure (history of radiotherapy, occupational exposure to radioactive materials) is also associated with tracheal cancer.
Chronic respiratory infection (recurrent pneumonia, tuberculous involvement of the trachea, chronic bronchitis) may provide an environment for cancer development through damage to the tracheal mucosa. Chronic irritation from tracheal foreign bodies or trauma is also rarely associated. Occupational exposure to chemicals (formaldehyde, vinyl chloride, etc.) is also reported as a risk factor. As genetic predispositions, tracheal tumors are rarely reported in NF-1 (neurofibromatosis), MEN1 (multiple endocrine neoplasia) and others.
Research data on the molecular genetics of tracheal cancer are limited because of its extremely low incidence. Squamous cell carcinoma (SCC): similar to head and neck and lung squamous cell carcinoma, TP53 variants, CDKN2A loss, EGFR overexpression, PIK3CA variants and CCND1 amplification are observed. Adenoid cystic carcinoma (ACC): with the same molecular features as salivary gland ACC, the MYB-NFIB fusion gene (about 30–50%) is most characteristic, causing constitutive activation of the MYB transcription factor and inducing cell proliferation and inhibition of apoptosis. NOTCH1 variants (about 10%) and KIT amplification (about 10%) are also reported in ACC. NTRK fusions are detected in some tracheal malignancies and may be an indication for tissue-agnostic therapy with larotrectinib/entrectinib. Molecular profiling (NGS panel) is recommended to explore rare gene variants and potential targeted therapies.
Tracheal cancer is an extremely rare cancer accounting for less than 0.1% of all malignancies, with an estimated 2,000 cases per year worldwide. About 400–600 cases are estimated to be diagnosed annually in the United States. It occurs more often in men than women at about 2:1 to 3:1, reflecting the sex difference in smoking-related squamous cell carcinoma. The median age at diagnosis is about 55–65 years.
Histologic distribution: squamous cell carcinoma about 50–60%, adenoid cystic carcinoma about 15–20%, others (mucoepidermoid carcinoma, carcinoid, small cell carcinoma, adenocarcinoma, chondrosarcoma, etc.) about 20–30%. ACC progresses relatively slowly and shows a peculiar natural history of survival for years to more than a decade, even though lung metastases are often already present at diagnosis. In Korea, tracheal cancer is classified in national cancer registry statistics as an extremely rare cancer with a few dozen cases per year.
Primary malignant tumors of the trachea have different mechanisms of development for the two main histologic types according to anatomic location. Squamous cell carcinoma (SCC): a multistep process of DNA damage to the tracheal respiratory epithelium by tobacco smoke carcinogens → squamous metaplasia → dysplasia → carcinoma in situ → invasive SCC. Because the cartilaginous rings of the trachea lack a posterior wall (membranous portion), esophageal invasion occurs easily when a tumor arises in the posterior tracheal wall. Adenoid cystic carcinoma (ACC): arises from the minor salivary glands (intestinal-type exocrine glands) of the tracheal submucosa, and constitutive activation of the MYB transcription factor by MYB-NFIB fusion explains its strong tendency toward perineural invasion. ACC commonly shows perineural invasion and hematogenous distant metastasis (mainly to the lung), but lymph node metastasis is relatively rare. The trachea has a rich vascular and lymphatic network, so tumors spread locally and rapidly if left untreated.
Diagnosis of tracheal cancer is delayed because early symptoms are very nonspecific and often mistaken for asthma, chronic bronchitis or recurrent pneumonia. Chronic cough is the most common early symptom and may persist for months to more than a year; malignancy should be suspected when it does not respond to antibiotics or bronchodilators. Hemoptysis occurs in about 40–50% and results from erosion of tumor vessels.
When about 75% or more of the airway lumen is obstructed, dyspnea and wheezing appear, and a fixed wheeze present in both inspiration and expiration is the characteristic auscultatory finding of tracheal stenosis. Dysphagia appears when the tumor invades or compresses the esophagus. Invasion of the recurrent laryngeal nerve causes hoarseness, and invasion of the superior vena cava (SVC) causes SVC syndrome (swelling of the face and upper limbs, jugular venous distension). With distant metastasis, weight loss, fatigue and symptoms of the affected organ appear.
On physical examination, biphasic (inspiratory and expiratory) wheeze is the characteristic auscultatory finding of central tracheal obstruction. Inspiratory wheeze (stridor) alone suggests upper airway obstruction. With severe airway obstruction, use of accessory respiratory muscles, chest wall retraction and cyanosis are observed. Hoarseness (recurrent laryngeal nerve palsy), SVC syndrome (swelling of the face and upper limbs, dilated scalp vessels) and lymphadenopathy (cervical, mediastinal) appear with progression. On spirometry, a characteristic pattern of flattening in both inspiration and expiration (fixed flattening) on the flow-volume curve suggests central airway obstruction.
Tracheal cancer is extremely rare, so there is no standard screening test. In high-risk groups (smokers, people exposed to asbestos), examination of the trachea on chest CT may occur incidentally during lung cancer screening, but no tracheal cancer-specific screening program exists. Clinically, when there is persistent wheezing, hemoptysis or cough unresponsive to treatment, immediate tracheoscopy (bronchoscopy) should be performed to rule out a central airway lesion. In patients followed for tracheal foreign bodies or stenosis, regular tracheoscopy can contribute to early detection of malignant transformation.
Flexible bronchoscopy is the most important diagnostic tool for directly observing the tracheal lumen and biopsying lesions. It assesses tumor location, extent (mediastinal trachea vs cervical trachea), degree of luminal obstruction and mucosal condition. With severe airway obstruction, biopsy can be performed while securing the airway with rigid bronchoscopy. Endobronchial ultrasound (EBUS) is used to assess invasion of peritracheal structures and lymph node metastasis.
Chest and neck CT assesses tumor location and extent, extratracheal invasion (esophagus, great vessels, mediastinum), cervical and mediastinal lymph node metastasis, and lung metastasis. MRI is used as a complement to assess soft tissue invasion and perineural invasion (particularly important in ACC). PET-CT is used to assess distant metastasis. Pulmonary function testing (flow-volume curve) is important for assessing the degree of airway obstruction and operability. Because a formal TNM staging system for tracheal cancer has not been fully standardized, many institutions use their own classification systems (tumor size, location within the trachea, extratracheal invasion, lymph node and distant metastasis).
Surgical resection is the only curative treatment for tracheal cancer. Tracheal resection and primary anastomosis allows resection of about 4–6 cartilage rings (about 4–6 cm or less); beyond that, the risk of anastomotic tension complications is high. A cervical approach is used for cervical tracheal tumors, and median sternotomy or right thoracotomy for transthoracic tracheal tumors. Neck flexion in the perioperative period reduces anastomotic tension. Complete resection (R0) is most important for prognosis, and the 5-year survival rate with R0 resection is markedly better than with R1/R2.
In inoperable patients, definitive radiotherapy (60–66 Gy) is given. Adjuvant radiotherapy is recommended after surgery for positive margins or high-risk features. Chemotherapy alone is used for palliative purposes; cisplatin-based regimens for SCC and cyclophosphamide-based regimens for ACC have been used, but evidence is limited. In MYB-NFIB fusion ACC, therapies targeting MYB inhibition are under study, and larotrectinib/entrectinib can be used in NTRK fusion-positive tracheal tumors. Palliative tracheal stent (silicone or metal stent) insertion is used for immediate symptom relief in unresectable patients with severe dyspnea due to airway obstruction. Laser ablation (Nd:YAG laser), electrocautery (APC) and cryotherapy are endoscopic palliative treatments that secure the airway lumen.
The prognosis of tracheal cancer depends heavily on histologic type and resectability. Adenoid cystic carcinoma (ACC) has a relatively favorable prognosis among tracheal malignancies, with a 5-year survival rate of about 52% and a 10-year survival rate of about 29%. ACC progresses slowly, and some patients survive for years even after lung metastasis. The 5-year survival rate of squamous cell carcinoma (SCC) is about 39%. With complete resection (R0), the 5-year survival rate is markedly higher than with incomplete resection (R1/R2) (about 60–70% vs 20–30%). Distant metastasis, mediastinal lymph node metastasis and extratracheal invasion are adverse prognostic factors. In overall tracheal cancer studies, according to a report in the European Journal of Cardio-Thoracic Surgery (2023), overall 5-year survival is about 52% (ACC) vs 39% (SCC), and higher in completely resected patients.
Smoking cessation: most effective in preventing tracheal squamous cell carcinoma. Reducing smoking duration and amount, and quitting early, suppress the carcinogenic process in the tracheal mucosa. Prevention of occupational asbestos and radiation exposure: wearing personal protective equipment (dust masks, protective clothing) for workers handling asbestos, and ventilation and sealing measures during asbestos removal. Dose minimization and monitoring for workers occupationally exposed to radiation. Active management of chronic respiratory disease: active treatment of underlying conditions causing chronic tracheal injury, such as chronic bronchitis, recurrent pneumonia and tuberculosis. Early removal of tracheal foreign bodies: early removal of intratracheal foreign bodies or tracheal stenosis to prevent chronic irritation. Reducing exposure to air pollution: minimizing exposure to air pollutants such as fine dust and sulfur dioxide.